These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 32654098)

  • 21. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
    Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
    Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
    Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hydroxychloroquine treatment on QT interval.
    Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
    Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
    Chorin E; Dai M; Shulman E; Wadhwani L; Bar-Cohen R; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Chinitz LA; Jankelson L
    Nat Med; 2020 Jun; 26(6):808-809. PubMed ID: 32488217
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
    Voisin O; Lorc'h EL; Mahé A; Azria P; Borie MF; Hubert S; Ménage E; Guillerm JC; Mourad JJ
    Mayo Clin Proc; 2020 Aug; 95(8):1696-1700. PubMed ID: 32753141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
    Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
    J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration-dependent mortality of chloroquine in overdose.
    Watson JA; Tarning J; Hoglund RM; Baud FJ; Megarbane B; Clemessy JL; White NJ
    Elife; 2020 Jul; 9():. PubMed ID: 32639233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
    Jiménez-Jáimez J; Macías-Ruiz R; Bermúdez-Jiménez F; Rubini-Costa R; Ramírez-Taboada J; Flores PIG; Gallo-Padilla L; García JDM; García CM; Suárez SM; Molina CF; López MÁ; Tercedor L
    Sci Rep; 2020 Dec; 10(1):21417. PubMed ID: 33293554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

  • 30. COVID-19 and QT interval prolongation: more than just drug toxicity?
    Merino JL; Martínez-Cossiani M; Iniesta A; Escobar C; Rey JR; Castrejón-Castrejón S
    Europace; 2020 Oct; 22(10):1479. PubMed ID: 32441761
    [No Abstract]   [Full Text] [Related]  

  • 31. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
    Gopinathannair R; Merchant FM; Lakkireddy DR; Etheridge SP; Feigofsky S; Han JK; Kabra R; Natale A; Poe S; Saha SA; Russo AM
    J Interv Card Electrophysiol; 2020 Nov; 59(2):329-336. PubMed ID: 32494896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
    Chotsiri P; Tarning J; Hoglund RM; Watson JA; White NJ
    Clin Pharmacol Ther; 2022 Oct; 112(4):824-835. PubMed ID: 35598114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
    Malviya A
    Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
    Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
    JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
    Moschini L; Loffi M; Regazzoni V; Di Tano G; Gherbesi E; Danzi GB
    Heart Vessels; 2021 Jan; 36(1):115-120. PubMed ID: 32676695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
    Zaidel EJ; Wyss Quintana FS; Sosa Liprandi Á; Mendoza I; Márquez MF; Nuñez E; Barbosa M; Baranchuk A
    Medicina (B Aires); 2020; 80(3):271-274. PubMed ID: 32442941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.
    Goldstein LH; Gabin A; Fawaz A; Freedberg NA; Schwartz N; Elias M; Saliba W
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1042-8. PubMed ID: 26238864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.
    Furtado RHM; Barros E Silva PGM; Fonseca HAR; Serpa-Neto A; Correa TD; Guimarães HP; Pereira AJ; Olivato GB; Zampieri FG; Lisboa T; Junqueira DLM; Lapa MG; Monfardini F; Damiani LP; Echenique LS; Gebara OE; Hoffman Filho CR; Polanczyk CA; Rohde LE; Amazonas R; Machado FR; Avezum A; Azevedo LCP; Veiga VC; Rosa RG; Lopes RD; Cavalcanti AB; Berwanger O;
    Am J Cardiol; 2024 Mar; 214():18-24. PubMed ID: 38104755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Potential harms associated with 4-aminoquinoline treatment].
    Svensson M
    Lakartidningen; 2020 Apr; 117():. PubMed ID: 32365215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.